On January 18, 2022 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported that it will have clinical data for its lead compound SCO-101 presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium taking place on January 20-22, 2022 (Press release, Scandion Oncology, JAN 18, 2022, View Source,c3486737 [SID1234605549]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pharmacokinetic data from part 1 of the CORIST Phase II-trial in patients with metastatic colorectal cancer will be announced at a poster presentation. These data will provide details to the topline results communicated earlier documenting the unique mode of action for SCO-101 which provides a significant potentiation of the chemotherapy Irinotecan when combined with the chemotherapy regimen FOLFIRI (which includes Irinotecan).
"We are very pleased to have these data accepted for presentation at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium, making it available to a large number of physicians and other stakeholders. We are excited by the data that confirms the potential of SCO-101 to significantly improve treatment options for patients", says Bo Rode Hansen, President & CEO of Scandion.
The combination of SCO-101 and FOLFIRI resulted in a dramatically increased exposure and half-life of SN-38, the active metabolite of Irinotecan. In other words, SCO-101 has the potential to make the chemotherapy much more effective without increasing side effects for patients.
Further to these findings, part 1 of the CORIST trial has also, as previously announced, helped establish a well-tolerated dose of SCO-101 in combination with FOLFIRI. Further, the trial identified the oncogene RAS as a predictive biomarker, helping to optimize patient inclusion in the ongoing second part of the trial, which is expected to conclude in the second half of 2022.
The abstract titled "Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI" will be published at the conference website later today: View Source